CLAIMS

1. ~~Pidotimod~~ The use of pidotimod or a physiologically acceptable salt thereof, ~~for use~~ in the manufacture of a medicament for the treatment of psoriasis.
2. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 1, characterized in that said psoriasis is skin psoriasis, nail psoriasis or psoriatic arthritis.
3. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 1, characterized in that ~~it~~ the medicament is to be administered to a human.
4. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 1, characterized in that ~~it~~ the medicament is to be administered systemically.
5. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 4, characterized in that ~~it~~ the medicament is to be administered by means of a solid or liquid formulation.
6. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 5, characterized in that said solid formulation is a tablet, a film-coated tablet, a capsule, a dragée or a sachet.
7. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 5, characterized in that said liquid formulation is a solution or a suspension.
8. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 5, characterized in that said solid formulation has a w/w concentration in pidotimod from 50% to 90%, more preferably from 65% to 80%, most preferably from 70% to 75%.
9. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 5, characterized in that said liquid formulation has a w/w concentration in pidotimod from 0.5% to 20%, more preferably from 1% to 10%, most preferably from 2% to 8%.
10. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 5, characterized in that said formulation has a content in pidotimod or a salt thereof, from 10 to 1000 mg per single dose, preferably from 50 to 800 mg per single dose.
11. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 1, characterized in that ~~it~~ the medicament is to be administered topically.

12. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 11, characterized in that ~~it~~ the medicament is to be administered by means of a semi-solid or liquid formulation.
13. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 12, characterized in that semi-solid formulation is a cream, a gel, an ointment or an emulsion.
14. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 12, characterized in that said liquid formulation is a solution or a suspension.
15. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 12, characterized in that said formulation has a w/w concentration in pidotimod or a salt thereof from 0.1% to 20%, preferably from 1% to 15%, more preferably from 5% to 10%.
16. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to any of the preceding claims, characterized in that ~~it~~ the medicament is administered in combination or in temporal proximity with at least one additional active principle.
17. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 16, characterized in that said at least one additional active principle is selected from immunosuppressive agents, Vitamin D and analogues, Vitamin A related compounds, corticosteroids, biologics.
18. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 17, characterized in that said at least one immunosuppressive agent is selected from: methotrexate, azathioprine, cyclosporine, fumaric acid, tacrolimus or pimecrolimus and corticosteroids.
19. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 17, characterized in that said at least one Vitamin D analogue is selected from calcitriol, calcipotriol and tacalcitol.
20. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 17, characterized in that said at least one Vitamin A related compound is selected from retinoids, tretinoine, isotretinoine, etretinate, acitretine, tazarotene, bexarotene and adapalene.

21. The~~Pidotimod or a physiologically acceptable salt thereof for~~ use according to claim 17, characterized in that said at least one biologic is selected from alefacept, etanercept, and monoclonal antibodies adalimumab, infliximab, ustekinumab.